Veterinary Pharmaceuticals Market

The veterinary pharmaceuticals market is worth USD 44,800.0 million in 2025 and reaches USD 77,822.1 million by 2035, compounding at 5.68% a year. The figure is built bottom-up: roughly 2.24 billion animal treatment courses administered in 2025 across companion animals and livestock, spanning parasiticides, vaccines, anti-infectives, and dermatology, pain and other specialty pharmaceuticals, at an average realised value of USD 20 per treatment course, triangulated against animal populations, veterinary visit data and animal health company disclosures. Treatment courses grow 3.2% a year as pet populations and livestock production expand, while value per course rises 2.4% a year as innovative companion animal medicines take share. This study sits within our pharmaceuticals coverage and follows the published Douglas Insights methodology.

Why has the companion animal segment outgrown livestock?

Because pet owners increasingly treat their animals as family members and spend on their health accordingly, while livestock medicine is governed by the economics of food production. For much of the animal health industry’s history, livestock medicines, used to keep cattle, pigs and poultry healthy and productive, were the larger business. Over the past two decades, spending on companion animals has grown far faster, as more households own pets, owners spend more per animal and veterinary care has become more sophisticated. Pet owners now buy monthly parasite protection, long acting dermatology treatments for itching, injectable monoclonal antibodies for arthritis pain, and treatments for chronic diseases that were once untreated, often paying for innovation in ways livestock producers, focused on cost per kilogram of meat or litre of milk, cannot. The result is that companion animal medicines carry higher prices and faster growth, and animal health companies have concentrated their innovation there. Livestock medicine remains large and essential, particularly vaccines and parasiticides that protect food production, but its growth is tied to livestock numbers and constrained by regulation on antibiotic use. The exclusive chapter of this report tracks spending per animal by species, since that metric captures the divergence.

What does this market include?

This study covers pharmaceutical products and vaccines used to prevent and treat disease in animals. Parasiticides cover products that control fleas, ticks, worms and other parasites in companion animals and livestock, the largest therapeutic category. Vaccines cover immunisations protecting companion animals and livestock against infectious diseases. Anti-infectives cover antibiotics, antifungals and antivirals used to treat infections. Dermatology, pain and other specialty pharmaceuticals cover treatments for allergic skin disease, osteoarthritis pain, chronic diseases and other conditions, predominantly in companion animals. Medicated and functional feed additives, including those covered in our separate animal nutrition coverage, veterinary diagnostics and imaging, pet food, and veterinary services fees sit outside the boundary. Value is measured at manufacturer realised price.

What is changing in livestock medicine?

Antibiotic use is being restricted while vaccines and disease prevention gain importance, driven by concern over antimicrobial resistance and by devastating disease outbreaks. For decades, antibiotics were used in livestock not only to treat sick animals but also to prevent disease and promote growth across whole herds and flocks, and this widespread use contributed to the rise of antimicrobial resistance that threatens human and animal health. Regulators have responded, with the European Union banning routine preventive use of antibiotics in groups of animals and other countries restricting growth promotion and requiring veterinary oversight. This shifts livestock health toward prevention through vaccines, biosecurity and management. At the same time, major disease outbreaks have highlighted the importance of vaccines and disease control: African swine fever devastated pig herds in Asia and Europe, prompting vaccine development, and highly pathogenic avian influenza has caused enormous losses in poultry and spread to dairy cattle, raising debate about vaccinating poultry against it. These forces reduce antibiotic volumes while supporting vaccine demand, reshaping the livestock segment.

What drives demand?

The first driver is pet ownership and spending. Growing pet populations, particularly dogs and cats, and rising willingness to spend on pet health drive companion animal medicine demand.

The second driver is innovation in companion animal medicine. New products, including long acting parasiticides, monoclonal antibodies for pain and allergy, and treatments for chronic diseases, create new categories and raise spending per animal.

The third driver is protein demand. Growing global demand for meat, milk and eggs increases livestock populations and the medicines needed to keep them healthy, particularly in emerging markets.

The fourth driver is disease threats. Outbreaks such as African swine fever and avian influenza drive demand for vaccines and disease prevention.

What restrains the market?

Three restraints are modelled. Antibiotic restrictions are the first: limits on antibiotic use in livestock reduce volumes in the anti-infective category. Pet owner price sensitivity and economic cycles are second: companion animal spending, while resilient, can soften in economic downturns, and generic competition affects older products. Safety concerns and regulatory scrutiny are third: some newer products have faced reports of adverse events, prompting regulatory attention and label updates, which can affect uptake.

Which categories carry the value?

Dermatology, pain and other specialty pharmaceuticals lead with 30% of 2025 value, USD 13,440.0 million, and grow fastest, driven by innovative companion animal treatments for allergic skin disease, osteoarthritis pain and chronic conditions. Parasiticides hold 28%, USD 12,544.0 million, including popular combination products that protect pets against multiple parasites. Vaccines account for 24%, USD 10,752.0 million, essential for both companion animals and livestock and growing with disease prevention. Anti-infectives contribute 18%, USD 8,064.0 million, facing restrictions in livestock. Each category is modelled through 2035 by species and region.

Where are veterinary medicines sold?

North America leads with 38% of 2025 value, USD 17,024.0 million, growing 5.2% a year, reflecting high pet ownership, high spending per pet and a large livestock sector. Europe holds 28%, USD 12,544.0 million, at 4.8%, with strong companion animal markets and strict antibiotic regulation. Asia Pacific holds 22%, USD 9,856.0 million, and grows fastest at 7.0%, driven by rising pet ownership in China and elsewhere and large, modernising livestock sectors. Latin America contributes USD 3,584.0 million at 6.4%, led by Brazil’s large livestock sector, the Middle East USD 896.0 million at 6.6% and Africa USD 896.0 million at 6.8%. Six regional models sum to the global figure, with country tables in the Excel model.

Who makes veterinary pharmaceuticals?

Zoetis is the largest animal health company, with leading positions in companion animal parasiticides, dermatology and pain treatments and in livestock products. Merck Animal Health, Boehringer Ingelheim Animal Health and Elanco are major competitors across companion animals and livestock. Ceva Santé Animale, Virbac, Vetoquinol, Dechra, now privately owned, and others hold strong positions in particular segments and regions. Chinese and Indian manufacturers supply large domestic markets, particularly livestock vaccines and generics. The competitive chapter profiles each company’s product portfolio by species and category, pipeline and regional presence.

How are veterinary medicines priced?

Average realised value is USD 20 per treatment course in 2025, a blend of very different price points. Livestock medicines are priced for large volumes and cost sensitive producers, often at low cost per animal or per dose. Companion animal medicines command much higher prices per treatment, with innovative products such as monoclonal antibodies and long acting parasiticides priced as premium branded treatments sold through veterinary clinics and, increasingly, online pharmacies. Generic competition lowers prices for older products once patents expire. The shift toward companion animal specialty medicines raises the average value per course over time, which is the reason for the positive price leg. The pricing chapter publishes price bands by species and category.

How do the scenarios diverge by 2035?

The base case carries 3.2% growth in treatment courses and 2.4% growth in value per course for a 5.68% revenue CAGR and USD 77,822.1 million in 2035. The spending-slowdown scenario, in which pet spending softens and livestock antibiotic restrictions tighten further, sets the legs at 2.0% and 1.2%, landing near USD 60,730 million. The innovation-led scenario, in which new companion animal therapies expand rapidly and livestock disease prevention grows, sets them at 4.2% and 3.6%, carrying the market past USD 94,600 million. Each 1-point change in course growth moves the 2035 figure by roughly USD 7,150 million.

Which rules and standards apply?

Three layers matter. Veterinary medicine approval comes first: animal medicines require approval demonstrating safety and efficacy for the target species, and for food producing animals, safety of residues in meat, milk and eggs, with withdrawal periods before animals enter the food chain. Antimicrobial regulation is second: restrictions on antibiotic use in livestock, requirements for veterinary prescription and bans on growth promotion shape the anti-infective market. Disease control and vaccination policy are third: government policies on disease control, including whether to allow vaccination against diseases such as avian influenza, affect vaccine demand and trade. The regulatory chapter maps these requirements by jurisdiction.

What does pet humanisation mean for the pipeline?

The treatment of pets as family members has changed the kind of medicines animal health companies develop, and increasingly the companion animal pipeline resembles human pharmaceutical innovation. Companies are developing monoclonal antibodies, a technology originally from human medicine, to treat chronic pain and allergic itching in dogs and cats with injections that last a month. They are pursuing treatments for chronic kidney disease, heart disease, cancer, diabetes and obesity in pets, conditions that owners now expect to be managed rather than accepted. Long acting formulations reduce how often owners must give medicines, improving compliance. This innovation carries higher prices and expands spending per pet, but it also brings the scrutiny that accompanies powerful new medicines, as reports of adverse events with some new products have shown. The model treats companion animal specialty medicines as the main engine of value growth, with the innovation led scenario capturing faster adoption of new therapies.

Douglas Exclusive: the spending per animal tracker

This report tracks, by species and region, animal populations, the share receiving veterinary care, treatment courses by category, and spending per animal, capturing the divergence between companion animal and livestock markets and converting population forecasts into medicine demand by category and region. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The model is built bottom-up from treatment courses: companion animal and livestock populations by region, veterinary care penetration, treatment courses by category and species, and realised prices from company disclosures, with feed additives, diagnostics and imaging, pet food and veterinary service fees excluded. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. The next scheduled review of this study is September 2027.